Back to results
US 2026/0146069 A1Published application
Recombinant opcml fusion protein optimizing opcml d1 domain homodimerisation and methods of use for cancer treatment
OwnerHani GABRA, Paul BLAKEinventors
Life of this patent
Estimating the term…
Abstract
Presented herein is a recombinant OPCML-Fc fusion protein molecule and methods of its use in cancer treatment where the Fc portion of the fusion protein molecule is only the CH2CH3 portion and lacks the hinge region containing the disulfide bridges preventing dimerization of the Fc portion and optimizing dimerization of the OPCML the D1 domain.
Claims23
A polypeptide molecule comprising an amino acid sequence having 95% identity to SEQ ID NO:
- 6.
A nucleic acid molecule comprising a nucleotide sequence encoding an amino acid sequence having at least 95% identity to SEQ ID NO:
- 6.
(canceled)
(canceled)
Dependencies are inferred from the claim text.